CD93 serves as a potential biomarker of gastric cancer and correlates with the tumor microenvironment

Figure 5 Gene mutation and tumor mutational burden comparison. A: Comparison of mutational landscapes between two groups; B: Comparison of tumor mutational burden between two groups; C: The mutation rate of CD93 in gastric cancer ranked fourth in pan-cancer. The P values are labeled as ^aP < 0.05, ^bP < 0.01, ^cP < 0.001.